Study identifier:D961WC00002
ClinicalTrials.gov identifier:NCT03562026
EudraCT identifier:N/A
CTIS identifier:N/A
Specific Clinical Experience Investigation of Nexium in paediatric patients
Peptic Ulcer, Gastroesophageal Reflux
N/A
No
-
All
240
Observational
N/A
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Sept 2021 by AstraZeneca
AstraZeneca
-
To capture safety and efficacy when Nexium are administered to pediatric patients in clinical practice after launch
The objective of this investigation is to capture the followings when Nexium capsules or Nexium granules for suspension (single-dose package) are administered to pediatric patients in clinical practice after launch. (1) Development of adverse reactions which are unexpected from Precaution for Use (2) Development of adverse reactions (3) Efficacy
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.